IV Drips Poison Dozens With Bacterial Toxins

Over 30 individuals across four U.S. states have been poisoned by bacterial toxins after receiving intravenous (IV) drips at wellness clinics, as reported by the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA). These patients received IV drips that contained glutathione, a substance promoted for unproven benefits such as detoxification, immune support, increased energy, and skin brightening. Glutathione is an antioxidant naturally present in the human body and has been investigated for potential therapeutic applications, but current scientific evidence offers little to no support for its efficacy in these contexts. Notably, there are no FDA-approved glutathione products available in the United States. Despite the lack of regulatory approval and robust scientific backing, glutathione is frequently utilized as a dietary supplement, most commonly in oral pill form. However, popular wellness clinics have increasingly offered IV infusions of vitamins and other supplements, including glutathione.

The critical issue identified by the CDC and FDA lies in the preparation of these injectable glutathione solutions. Specialty drug manufacturers, known as compounding pharmacies, are reportedly using glutathione powders that are graded for oral dietary supplements. This grading is fundamentally different from the purification standards required for sterile injectable drugs. Products intended for oral consumption do not undergo the rigorous testing and purification processes necessary to ensure sterility and safety for intravenous administration. The use of non-sterile, orally-graded glutathione powder in IV drips creates a significant risk of contamination with harmful bacteria and their toxins, leading to severe adverse health events.

The CDC and FDA are actively investigating these cases to identify the specific compounding pharmacies responsible and the exact source of the contamination. Public health officials are urging healthcare providers and consumers to exercise extreme caution regarding IV glutathione infusions. The agencies recommend that any glutathione products intended for injection must be prepared by pharmacies that meet sterile drug compounding standards and use ingredients specifically graded for parenteral use. This incident highlights the potential dangers associated with unregulated or improperly prepared supplements administered intravenously, underscoring the importance of adhering to strict pharmaceutical manufacturing and compounding guidelines to protect patient safety. Further details regarding the specific clinics involved and the number of affected individuals in each state are expected to be released as the investigation progresses.